Flow cytometry of hematological malignancies / / Claudio Ortolani

• Autore: Ortolani C (Claudio)
• Pubblicazione: Hoboken, New Jersey ; ; Chichester, West Sussex, England : , : Wiley Blackwell, , [2021]; ©2021
• Edizione: Second edition.
• Descrizione fisica: 1 online resource (467 pages)
• Disciplina: 574.87028
• Soggetto topico: Flow cytometry; Hematological oncology; Flow cytometry - Methodology
• Nota di bibliografia: Includes bibliographical references (pages 301-428) and index.
• Nota di contenuto: Cover -- Title Page -- Copyright Page -- Contents -- Foreword to the Second Edition -- Foreword to the First Edition -- Foreword to the First Edition -- Preface to the Second Edition -- Preface to the First Edition -- Abbreviations -- Chapter 1 Antigens -- CD1 Antigens -- CD2 Antigen -- CD3 Antigen -- CD4 Antigen -- CD5 Antigen -- CD7 Antigen -- CD8 Antigen -- CD10 Antigen -- CD11b Antigen -- CD11c Antigen -- CD13 Antigen -- CD14 Antigen -- CD15 Antigen -- CD16 Antigen -- CD19 Antigen -- CD20 Antigen -- CD22 Antigen -- CD23 Antigen -- CD24 Antigen -- CD25 Antigen -- CD26 Antigen -- CD27 Antigen -- CD28 Antigen -- CD30 Antigen -- CD33 Antigen -- CD34 Antigen -- CD38 Antigen -- CD43 Antigen -- CD45 Antigen -- CD45 Isoforms -- CD49 Antigens -- CD56 Antigen -- CD57 Antigen -- CD61 Antigen -- CD62L Antigen -- CD64 Antigen -- CD65 Antigen -- CD66c Antigen -- CD71 Antigen -- CD79 Antigen -- CD81 Antigen -- CD103 Antigen -- CD117 Antigen -- CD123 Antigen -- CD138 Antigen -- CD200 Antigen -- CD305 Antigen -- CD307 (IRTA) Family -- CD371 Antigen -- BCL-2 Protein -- Chemokines and Chemokine Receptors -- Chemokines -- Chemokine Receptors -- CRLF2 Antigen -- Cytotoxic Proteins -- HLA-DR Antigen -- Immunoglobulins -- KIRs, CD158 Isoforms -- Myeloperoxidase -- NG2 Antigen -- PCA-1 Antigen -- ROR1 Antigen -- SLAM Molecules and SLAM-Associated Protein -- SOX11 -- T-Cell Receptor (TCR) -- Terminal Deoxy-Nucleotidyl Transferase -- Toll-Like Receptors -- VS38 Antigen -- ZAP-70 Protein -- Chapter 2 Diseases -- Myeloproliferative neoplasms -- Chronic myeloid leukemia (CML) -- Myeloproliferative neoplasms other than CML -- Chronic neutrophilic leukemia (CNL) -- Polycythemia vera (PV) -- Primary myelofibrosis (PMF) -- Essential thrombocythemia (ET) -- Chronic eosinophilic leukemia (CEL) -- Mastocytosis -- Acute mast-cell leukemia (AMCL). ; Chronic mast-cell leukemia (CMCL) -- Myelomastocytic leukemia (MML) -- Myelodysplastic/myeloproliferative neoplasms -- Chronic myelomonocytic leukemia (CMML) -- Other myelodysplastic/myeloproliferative neoplasms and related conditions -- Juvenile myelomonocytic leukemia (JMML) -- Atypical CML bcr/abl negative (ACML) -- RAS-associated autoimmune leukoproliferative disorder (RALD) -- Myelodysplastic syndromes -- Myeloid neoplasms with germline predisposition -- Acute myeloid leukemias -- AMLs with recurrent genetic anomalies -- AMLs with chromosomal anomalies -- AMLs with gene mutations -- Relationships between genotype and phenotype in cases of AML not recognized as separate entities in WHO 2017 -- AMLs with myelodysplasia-related changes (AML-MRC) -- AMLs not otherwise specified -- AML with minimal differentiation -- AML without maturation -- AML with maturation -- Acute myelomonocytic leukemia (AMMoL) -- Acute monoblastic and monocytic leukemia (AMoL) -- Pure erythroid leukemia (PEL) -- Acute megakaryoblastic leukemia (AMKL) -- Acute basophilic leukemia (ABL) -- Myeloid proliferations associated with Down syndrome -- Transient abnormal myelopoiesis (TAM) -- AMLs in patients with Down syndrome -- Blastic plasmacytoid dendritic cell neoplasm (BPDCN/PDCL) -- Acute leukemias with ambiguous lineage attribution (ALAL) -- Acute undifferentiated leukemias (AUL) -- Mixed phenotype acute leukemias (MPAL) -- Neoplastic diseases of B and T lymphatic precursors -- B lymphoblastic leukemia/lymphoma, not otherwise specified (B-ALL/LBLnos) -- B lymphoblastic leukemia/lymphoma with recurrent genetic anomalies -- Relationships between genotype and phenotype in cases of B-ALL not recognized as separate entities in WHO 2017 -- T lymphoblastic leukemia/lymphoma (T-ALL/LBL) -- Early T-cell precursor lymphoblastic leukemia (ETP-ALL). ; NK lymphoblastic leukemia/lymphoma (NK-ALL/LBL) -- Neoplastic diseases of mature B cells -- Chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) -- Familial B-CLL -- Richter syndrome -- Monoclonal B-cell lymphocytosis (MBL) -- CLL-like monoclonal B lymphocytosis -- Non-CLL-like monoclonal B lymphocytosis -- B-cell prolymphocytic leukemia (B-PLL) -- Lymphoplasmacytic lymphoma (LPL) -- Heavy chain disease (HCD) -- μ heavy chain disease -- α heavy chain disease -- Hairy cell leukemia (HCL) -- Hairy cell leukemia, variant (HCL-v) -- Hairy cell leukemia, Japanese variant (HCL-J) -- Splenic diffuse red pulp lymphoma (SDRPL) -- Marginal zone lymphomas (MZL) -- Nodal marginal zone lymphoma (NMZL) -- Splenic marginal zone lymphoma (SMZL) -- Extranodal marginal zone lymphoma (EMZL/MALToma) -- Clonal B-cell lymphocytosis with MZL-like phenotype (CBL-MZ) -- Follicular lymphoma (FCL) -- Testicular follicular lymphoma -- Duodenal type follicular lymphoma -- Pediatric type follicular lymphoma -- Primitive cutaneous follicular lymphoma (PCFL) -- Large B-cell lymphoma with IRF4 rearrangement -- Mantle-cell lymphoma (MCL) -- Blastic mantle-cell lymphoma (BMCL) -- Leukemic non nodal mantle-cell lymphoma -- DLBCL not otherwise specified (DLBCLnos) -- CD5(+) diffuse large cell lymphoma (CD5(+) DLBCL) -- T-cell/histiocyte-rich B-cell lymphoma (THRLBCL) -- Primary DLBCL of the CNS (PCNSL) -- Primary cutaneous DLBCL, "leg type -- EBV(+) DLBCLnos -- DLBCL associated with chronic inflammation (PAL) -- Fibrin associated DLBCL -- Lymphomatoid granulomatosis (LYG) -- Primary mediastinal B-cell lymphoma (PMBCL) -- Intravascular large B-cell lymphoma (IVBCL) -- ALK-positive large cell lymphoma (ALK(+) LBCL) -- Plasmablastic lymphoma (PBL) -- Primary effusion lymphoma (PEL) -- HHV8-associated lymphoproliferative disorders -- HHV8-positive DLBCL. ; HHV8-positive germinotropic lymphoproliferative disorder -- Burkitt lymphoma (BL) -- Burkitt leukemia with immature phenotype -- Burkitt-like lymphoma with 11q aberrations -- High-grade B-cell lymphoma (HGBL) -- Plasma cell neoplasms -- Monoclonal gammopathies of undetermined significance (MGUS) -- Multiple myeloma (MM) -- Plasma cell leukemia (PCL) -- Neoplastic diseases of mature T and NK cells -- T-cell prolymphocytic leukemia (T-PLL) -- T-cell large granular lymphocytic leukemia (T-LGL) -- Chronic lymphoproliferative disorders of NK cells (CLPD-NK/CNKL) -- Aggressive NK-cell leukemia (ANKL) -- Adult T-cell leukemia/lymphoma (ATLL) -- Extranodal NK/T-cell lymphoma, "nasal type" (ENKTL) -- Intestinal T-cell lymphomas (ITCL) -- Enteropathy-associated T-cell lymphoma (EATCL) -- Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) -- Indolent gastro-intestinal T lymphoproliferative disorder (indolent GI T-LPD) -- Hepatosplenic T-cell lymphoma (HSTCL) -- Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) -- Mycosis fungoides (MF) -- Sezary syndrome (SS) -- Primary cutaneous CD30(+) lymphoproliferative disorders -- Lymphomatoid papulosis (LyP) -- Primary cutaneous anaplastic T-cell lymphoma (pcALCL) -- Primary cutaneous peripheral T-cell lymphoma (PTCL) -- Primary cutaneous TCRƒÁƒÂ(+) T-cell lymphoma (PCGD-TCL) -- Primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma (PCAETL) -- Primary cutaneous acral CD8(+) T-cell lymphoma (PCATCL) -- Primary cutaneous lymphoma of the medium/small CD4(+) T cells (PCSM-TCL) -- Peripheral T-cell lymphoma, not otherwise specified (PTCLnos) -- Nodal lymphomas of follicular T-helper derivation -- Angioimmunoblastic T-cell lymphoma (AITL) -- Follicular T-cell lymphoma (FTCL) -- Nodal PTCL with follicular T-helper phenotype -- Anaplastic large cell lymphoma ALK(+) (ALCL ALK(+)). ; Anaplastic large cell lymphoma ALK(-) (ALCL ALK(-)) -- Breast implant.associated anaplastic large cell lymphoma (biaALCL) -- Hodgkin lymphomas -- Classic Hodgkin lymphoma (CHL) -- Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) -- Neoplastic diseases of histiocytic and dendritic cells -- Histiocytic sarcoma (HS) -- Langerhans cell histiocytosis (LCH) -- Indeterminate dendritic cell tumor (IDCT) -- Interdigitating dendritic cell sarcoma (IDCS) -- Follicular dendritic cell sarcoma (FDCS) -- Erdheim.Chester disease (EDC) -- Chapter 3 Appendix -- Acute leukemias not recognized by the 2017 WHO classification -- Acute leukemia of myeloid/NK precursors (M/NK-AL) -- Acute leukemia of myeloid dendritic cells (MDCL) -- Acute leukemia of Langerhans cells -- Composite lymphomas -- Hypereosinophilic syndrome (HES), lymphocyte variant -- Indolent T lymphoblastic proliferations (iT]LBP) -- Polyclonal lymphocytoses of B lymphocytes -- Persistent polyclonal B]cell lymphocytosis (PPBL) -- Persistent polyclonal CD5(+) B]cell lymphocytosis -- Persistent polyclonal B]cell lymphocytosis, Japanese (hairy) variant -- Polyclonal plasmacytoses -- Small round (blue) cell tumors (SR(B)CT) -- References -- Index -- EULA.
• Sommario/riassunto: "Flow Cytometry of Hematological Malignancies contains an array of graphical outputs produced by the technique in the study of the most (and the least) common diseases. The images included allow you to compare your own results with a third party reference pattern. There is a detailed description of the main leukocyte antigens, together with a description of their distribution amongst normal and abnormal blood cells. The book also provides a comprehensive description of the phenotype of every neoplastic blood disease recorded in the WHO classification system, including all the instructions needed to recognise and classify even the least common entity. Designed to be practical, the book is perfect for quick consultation and is divided into two main sections. Section I deals with the direct object of immunophenotyping, and Section II deals with the ultimate target of the analysis. More than 50 antigens are covered and every antigen is dealt with in three main parts: general features, cytometric features and practical hints. This authoritative and state-of-the-art reference will be invaluable for clinicians directly involved in the diagnosis and analysis of hematological diseases, including hematologists, hematopathologists, oncologists, pathologists and technicians working in diagnostic laboratories"--
• Titolo autorizzato: Flow cytometry of hematological malignancies
• ISBN: 1-119-61130-X; 1-119-61127-X; 1-119-61128-8
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910829962903321
• Lo trovi qui: Univ. Federico II